Therapeutic effect of Zhibitai combined with atorvastatin in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of hypersensitive C-reactive protein
10.3760/cma.j.issn.1008-6706.2019.24.020
- VernacularTitle: 脂必泰联合阿托伐他汀治疗冠状动脉粥样硬化性心脏病合并高脂血症的疗效及对超敏C-反应蛋白水平的影响
- Author:
Ting LU
1
;
Bin TAN
2
;
Tingting DENG
1
;
Yongping HUA
1
;
Gang XI
1
Author Information
1. Department of The Second Cardiology, the Third People's Hospital of Jingdezhen, Jingdezhen, Jiangxi 333000, China
2. Department of Emergency, the Third People's Hospital of Jingdezhen Jingdezhen, Jiangxi 333000, China
- Publication Type:Journal Article
- Keywords:
Coronary artery disease;
Hyperlipidemias;
Lipoproteins, HDL;
Cholesterol, LDL;
C-Reactive protein;
Triglycerides;
Adverse reactions;
Zhibitai;
Atorvastatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(24):3022-3025
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the effect of atorvastatin combined with Zhibitai in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of high-sensitivity C-reactive protein(hsCRP).
Methods:A total of 136 patients with coronary heart disease and hyperlipidemia admitted to the Third People's Hospital of Jingdezhen from September 2016 to September 1818 were randomly divided into control group and combination group using stochastic comprehensive balance method, with 68 cases in each group.The control group was treated with atorvastatin and the combination group was treated with lipidine plus atorvastatin. The patient's treatment effect, including the blood lipid compliance rate and the occurrence of adverse reactions during the treatment were observed, as well as the patient's pre-and post-treatment triglyceride(TG), 12h serum total cholesterol(TC), high-density lipoprotein-cholesterol(HDL-C), low density lipoprotein-cholesterol(LDL-C)and high-sensitivity C-reactive protein(hsCRP)and other indicators were measured.
Results:(1)The blood lipid compliance rate(89.86%) in the combined group was higher than that in the control group(59.70%), the difference was statistically significant(χ2=14.915, P=0.000). (2)The incidence of adverse reactions in the combined group(1.45%) was lower than that in the control group(17.91%), the difference was statistically significant(χ2=8.836, P=0.003). (3)The results showed that the TC, TG, LDL-C, hsCRP and other indicators of the combined group were lower than those of the control group and before treatment, while the HDL-C index of the combined groupwas higher than that of the control group and before treatment, the differences were statistically significant(t=20.800, 4.903, 11.657, 4.346, 6.262, P=0.000, 0.000, 0.000, 0.000, 0.000).
Conclusion:Zhibitai combined with atorvastatin in the treatment of coronary heart disease patients with hyperlipidemia has remarkable effect.It can accurately control TC, TG, LDL-C, HDL-C and hsCRP, improve blood lipid control rate.
